semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Asthma Main ≥ Age 12 years at the Screening Visit History of asthma for 12 months prior to the Screening Visit Documented use of an inhaled corticosteroid for at least 4 weeks prior to the Screening Visit Steroid-requiring patient patients must demonstrate (1) an FEV1 of 40% to 80% (inclusive) of predicted normal values at both the Screening and Baseline Visits and (2) documented reversibility within 12 months of the Screening Visit, defined as a ≥ 15% Main  Life-threatening asthma within the past year or during the Run-In Period History of systemic (oral or injectable) corticosteroid medication within 3 months before the Screening Visit An upper or lower respiratory infection within 4 weeks prior to the Screening Visit or during the Run-In Period Significant, non-reversible, pulmonary disease (e.g., chronic obstructive pulmonary disease [COPD], cystic fibrosis, bronchiectasis) A smoking history equivalent to "10 pack years" (i.e., at least 1 pack of 20 cigarettes /day for 10 years or 10 packs/day for 1 year, etc.) Current smoking history within 12 months prior to the Screening Visit Previous exposure to FlutiForm
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Asthma Diagnosis of asthma and baseline lung function tests, symptoms and medication use as determined by the protocol Required and received treatment with inhaled corticosteroids within the timeframe and doses specified in the protocol  Has required treatment with non-inhaled corticosteroids within previous 30 days, has sensitivity to drugs specified in the protocol or requires treatment with a beta-blocker Has had cancer within previous 5 years or has a condition that may put the patient at risk in this study
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 5.0-18.0,  Asthma All children and adolescents (5-18 years) with asthma in Tayside (Scotland) known To carry the Arg/Arg-16 genotype and Currently on inhaled steroids and Inhaled bronchodilators according to need will be telephoned or contacted through home visits to establish if they have had Any school absences from asthma or Out-of-hours visits to GP/hospital visits or admissions due to asthma over the previous 12 months  The presence of serious respiratory or multi-system disease (e.g. cystic fibrosis, cancer under current treatment)
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Asthma for severe asthmatics Physician diagnosis of asthma Aged 18 Non-smokers or ex-smokers with less than 5 pack/year history Major characteristics (at least one of the following criteria) Treatment with continuous or near continuous (>50% of year) oral corticosteroids Requirement for treatment with high dose inhaled corticosteroids (ICS) Minor characteristics (at least 2 out of the following) 1. Requirement for daily treatment with a controller medication in addition to ICS e.g. LABA, theophylline, leukotriene antagonist 2. Asthma symptoms requiring SABA on a daily or near daily basis 3. Persistent airways obstruction (FEV1 <80% predicted, diurnal PEF variation >20%) 4. One or more emergency care visits for asthma per year 5. 3 or more steroid "bursts" per year 6. Prompt deterioration with ≤ 25% reduction in oral or ICS 7. Near fatal asthma event in the past for moderately-severe asthma Physician diagnosis of asthma  Current smokers, or less than 3 years since quitting smoking Less than 4 weeks from an exacerbation Diabetes Active peptic ulceration Previous history of psychiatric disturbances on high dose prednisolone On steroid-sparing agent or immunosuppressant such as azathioprine, methotrexate and ciclosporin Concomitant anti-IgE therapy Pregnancy
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Asthma Male and female subjects must be at least greater than or equal to 18 years of age at the time of consent Subjects must have history of asthma for at least 6 months Subjects must present to the emergency department (ED) or clinic with forced expiratory volume in one second (FEV1) of 20 to 55% (inclusive) predicted at baseline Subjects must have O2 saturation greater than or equal to 90% at room air or with no more than 6 Liters/minute supplemental oxygen and no other cause of wheezing or shortness of breath other than asthma as determined by the physician Prior use of a beta-agonist (e.g., Primatine Mist, albuterol, salmeterol, etc.) within 24 hours of presentation to the ED or Clinic Smoked ≤ 10 pack-years or non-smoker Be in good health with the exception of asthma and not suffering from any chronic condition which might affect their lung function, such as COPD or emphysema Near-normal activity level between exacerbations Subjects who are taking inhaled or systemic corticosteroids must be on a stable dose for at least 21 days prior to study entry  Subjects who have received treatment for asthma in an ED, Clinic, or Urgent Care Center within 2 weeks prior to study entry Based upon history or physical exam in the ED or Clinic, subjects with known or suspected cause of pulmonary symptoms other than asthma, such as COPD, CHF, pneumonia, pulmonary embolism, or angioedema Subjects with a history of asthma episodes associated with hypercapnia, respiratory arrest, hypoxic seizures, or requiring intubation within 12 months prior to entry Hospitalization for asthma within two months prior to entry Female subjects who are pregnant or lactating Subjects who have a history of a clinically significant psychiatric disorder within the last 3 months, with the exception of mild depression Subjects who have participated in an investigational drug study within 30 days of study entry or have previously participated in the current trial
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 7.0-18.0,  Asthma Male or female aged 7 to 18 years Mild to moderate asthma diagnosed by a respirologist Use of budesonide at a dose of 200-800 µg/d (or equivalent corticosteroid therapy) for ≥3 months Stable asthma, defined as no significant change in the regular asthma medication and no acute asthma exacerbation requiring corticosteroid rescue for at least 3 months before enrollment in the run-in phase. Asthma symptoms must be under good control Baseline forced expiratory volume at 1 second (FEV-1) >= 70% of the predicted normal value Possible participants treated with orthomolecular therapies within the previous year will require a wash out period of 7 days prior to enrolment in the trial. (Vitamin C > 200mg, Vitamin E >50IU, Vitamin B12 > 100µg, Magnesium > 200mg, Selenium > 50µg, Omega-3 > 300mg, Quercetin > 3mg, Vitamin B6 > 75mg will all be considered orthomolecular doses)  Known hypersensitivity to any component of the orthomolecular therapy or placebo Acute infectious sinusitis or respiratory tract infection or active lung disease other than allergic asthma within 1 month or any other significant systemic disease within 3 months of the study entry visit
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 10.0-999.0,  Asthma Diplotype: Whites with specific diplotype and African Americans with specific diplotypes Gender: Male or female. Women are eligible if they are not pregnant or lactating. Females subjects of childbearing potential will undergo a urine pregnancy test prior to each methacholine challenge test Age: 10 years and older Asthma Diagnosis: Physician diagnosed asthma according to American Thoracic Society for at least 3 months Asthma Therapy: There is no requirement for previous asthma therapy to be included in this study Asthma Severity: forced expiratory volume in the first second (FEV1) must be >= 60% of predicted normal values for age, height, and gender methacholine challenge test provocative concentration (20% fall in FEV1) of <=12]mg/ml  History of life-threatening asthma: Any episode of asthma requiring intubation associated with hypercapnia, respiratory arrest, or hypoxic seizures Asthma instability: Hospitalization for asthma within 3 months of Visit 1 Concurrent respiratory disease: Any respiratory disease other than asthma Sensitivities: Sensitivities to methacholine, Flovent® MDI, ipratropium bromide, albuterol, or Advair Diskus® that would put the safety of the subject at risk Respiratory Tract Infection: Any sinus, middle ear, oropharyngeal, upper or lower respiratory tract infection that has not resolved at least 2 weeks immediately preceding Visit 1, or for which antibiotic therapy has not been completed at least 2 weeks prior to Visit 1 Expected exposure to pollen allergen to which the patient is sensitive (by medical history of symptoms) during the 29 day study period. These patients can be studied when pollen exposure to which they are sensitive will not occur
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-75.0,  Asthma, Exercise Induced Physician diagnosed asthma Age 12-75 yrs FEV1 > 70% predicted HIB response > 10 % No smoking last 6 mo and < 10 pack yrs No URI last 4 weeks No asthma exacerbation last 4 weks Able to withhold SABA > 8 hrs and LABA > 24 hrs  Other lung disease Cardiac disease or other condition that would preclude safe participation, on theophylline or leukotriene modifiers
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Healthy Smokers current smoker healthy  no asthma no chronic health conditions no daily cough not pregnant or nursing a baby not actively trying to get pregnant or father a child
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Asthma Key Clinical diagnosis of Asthma Reversibility ≥ 12% and ≥200mls reversibility of FEV1 within approximately 30-minutes following 2 to 4 puffs of albuterol FEV1 between 40-85% predicted Currently on short acting beta2 agonist therapy Key  History of life threatening asthma Respiratory Infection or oropharyngeal candidiasis Asthma exacerbation Uncontrolled disease or clinical abnormality Allergies Taking another Investigational medications or other prohibited medications
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-80.0,  Asthma Ages 12-80 years. [NOTE: Only the Johns Hopkins site will enroll subjects under 18.] Clinical history consistent with asthma (GINA 4 definitions) for at least six months Current symptoms and features of partly-controlled or uncontrolled asthma, according to GINA classification of asthma control A stable (1 month) treatment regimen consisting of as needed short-acting bronchodilators alone as needed short-acting bronchodilators in combination with low or medium-dose inhaled corticosteroids (<= 1000 mcg per day beclomethasone or equivalent any combination of long acting beta-agonist bronchodilator and low or medium-dose inhaled corticosteroid (as defined above),as needed short-acting bronchodilators in combination with montelukast or other leukotriene modifier Willingness to comply with the study protocol and ability to perform the study procedures  Pulmonary disease other than asthma, such as smoking-related chronic obstructive pulmonary disease (COPD), clinically significant bronchiectasis, lung resection, and interstitial lung disease Other significant systemic illness which might, in the opinion of the investigator alter the risk or outcome of the study (e.g. cardiovascular arrhythmias or conduction abnormalities, hyperthyroidism, uncontrolled hypertension, cancer) Tobacco smoking greater than 10 pack-year of cumulative exposure or current smoking within 10 years Respiratory tract infection within 6 weeks of the study Seasonal allergies causing symptoms within the past 4 weeks. Perennial or out of season allergic rhinitis is acceptable. Nasal corticosteroids and long-acting antihistamines are acceptable Any investigational drug or treatment within 30 days Use of cromolyn, nedocromil, theophylline, tiotropium, or oral albuterol within 1 week prior to Visit 1 of the study Current use of omalizumab or within the last 8 weeks Subjects on anti-depressant (mono-amine oxidase inhibitors or tricyclic antidepressants) treatment within 8 weeks Non-potassium sparing diuretics unless in fixed combination with potassium-sparing diuretics within one week
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Asthma Obesity Asthma diagnosed by a physician at least 1 year prior to study enrollment Poorly-controlled asthma at study enrollment Non smokers (stopped smoking at least 1 year ago) and limited lifetime history of smoking Body mass index 30-60 Responds to methacholine challenge test with PC20 of <16 mg/ml On a stable dose of inhaled corticosteroid for at least 4 weeks prior to study entry FEV1 > 60% predicted Able to obtain weekly weights at home  Systemic steroids within the past 4 weeks Lung pathology other than asthma Other significant non-pulmonary co-morbidities such as: coronary artery disease, peripheral vascular disease, cerebrovascular disease, congestive heart failure with an ejection fraction <50%, liver disease or elevated liver enzymes at baseline, malignancy (excluding non-melanoma skin cancers), AIDS, renal failure with serum creatinine >3.0, or disorders requiring steroid treatment such as vasculitis, lupus, rheumatoid arthritis B-type natriuretic peptide (BNP) >400pg/ml Pregnant or lactating Currently taking a beta blocker, a CYP2C8 inhibitor or inducer such as gemfibrozil or rifampin, a TZD (thiazolidinedione), or allergic to TZD Taking antioxidants (if taking a multivitamin must be on a stable regimen prior to enrollment) Illicit drug use within the past year Current/active upper respiratory infection (if active URI, wait until asymptomatic for 1 week to enroll) Asthma exacerbation within the past 4 weeks (includes ER, urgent care, or hospital visits due to asthma resulting in an increase in asthma-related medications)
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Asthma He or she has FEV1 > 60% of predicted He or she requires less than 1000 mcg daily of beclomethasone or equivalent  He or she had previous history of renal disease or serum creatinine more than 2 mg/dL He or she had previous history of liver disease She is pregnant or during lactation He or she has already received statins or is allergic to statins or has developed myositis He or she has an asthma exacerbation and requires treatment with oral corticosteroids during the 3 months prior to the commencement of study entry